ESR1 and endometrial cancer: Data from the Gynecologic Oncology Group (GOG) Core Laboratory for Receptors have shown that ER-α on a pretreatment biopsy predicts response to hormonal therapy in GOG study 119, tamoxifen and intermittent medroxyprogesterone acetate for advanced endometrial cancer [38].